Leukemia escapes immunity by imposing a Type-1 regulatory program on neoantigen-specific CD4+ T cells

Area of Science:

• Immunology
• Oncology
• Hematology

Background:

• The role of immune surveillance in acute lymphoblastic leukemia (ALL) is debated.
• Leukemic cells may evade immune detection through specific microenvironmental interactions.

Purpose of the Study:

• To investigate the function of neoantigen-specific CD4+ T cells in the ALL microenvironment.
• To elucidate the mechanisms by which leukemic cells evade immune surveillance and promote relapse.
• To evaluate therapeutic strategies targeting T cell regulation in ALL.

Main Methods:

• Utilized clinical B-ALL samples and a novel mouse model.
• Analyzed T cell phenotypes and functions within the leukemia microenvironment.
• Assessed therapeutic efficacy of IL10 receptor blockade, cytotoxic agents, and anti-PDL1 blockade.

Main Results:

• Neoantigen-specific CD4+ T cells differentiate into type-1 regulatory T cells (Tr1s) in the ALL microenvironment.
• Tr1s inhibit cytotoxic CD8+ T cells, hindering leukemia clearance and promoting relapse.
• Combined cytotoxic therapy and anti-PDL1 blockade eradicated measurable residual disease in mouse models.
• This therapeutic approach polarized CD4+ T cells from Tr1 to Th1 states.

Conclusions:

• Leukemic cells hijack CD4+ T cells, converting them into Tr1s that suppress anti-leukemia immunity.
• This mechanism explains immune evasion and relapse in ALL, resolving controversies about immune surveillance.
• Therapeutic strategies aimed at polarizing CD4+ T cells towards Th1 states hold promise for improving ALL immunotherapy.